Naveena Singh
A5084183460- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Cervical Cancer and HPV Research
- Cancer Genomics and Diagnostics
- Endometriosis Research and Treatment
- Colorectal and Anal Carcinomas
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related molecular mechanisms research
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- Reproductive System and Pregnancy
- Cancer Mechanisms and Therapy
- Sarcoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Congenital Diaphragmatic Hernia Studies
- Neonatal Respiratory Health Research
- Renal cell carcinoma treatment
- Chromatin Remodeling and Cancer
- Intraperitoneal and Appendiceal Malignancies
- Reproductive Biology and Fertility
- Immune cells in cancer
- Genital Health and Disease
- Cancer-related Molecular Pathways
Barts Health NHS Trust
2016-2025
Massachusetts General Hospital
2005-2024
Royal Women's Hospital
2021-2024
University of California, San Francisco
2021-2024
University of British Columbia
2015-2024
Vancouver General Hospital
2015-2024
The Christie NHS Foundation Trust
2024
Yahoo (United Kingdom)
2023-2024
Royal Children's Hospital
2024
Memorial Sloan Kettering Cancer Center
2018-2024
Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 years. We designed this trial to establish the effect early detection by screening on ovarian mortality.
Ovarian cancer has a high case-fatality ratio, with most women not diagnosed until the disease is in its advanced stages. The United Kingdom Collaborative Trial of Cancer Screening (UKCTOCS) randomised controlled trial designed to assess effect screening on mortality. This report summarises outcome prevalence (initial) screen UKCTOCS.Between 2001 and 2005, total 202 638 post-menopausal aged 50-74 years were randomly assigned no treatment (control; n=101 359); annual CA125 (interpreted using...
The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus alone (RT) for women with high-risk endometrial cancer (EC). Because Genome Atlas defined an EC molecular classification strong prognostic value, we prognosis impact each subgroup using tissue samples from PORTEC-3 participants.Paraffin-embedded tissues 423 consenting patients...
BackgroundAlthough women with endometrial cancer generally have a favourable prognosis, those high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic alone for cancer.MethodsPORTEC-3 an open-label, international, randomised, phase 3 involving 103 centres in six clinical trials collaborating Gynaecological Cancer Intergroup. Eligible had...
BackgroundOvarian cancer continues to have a poor prognosis with the majority of women diagnosed advanced disease. Therefore, we undertook UK Collaborative Trial Ovarian Cancer Screening (UKCTOCS) determine if population screening can reduce deaths due We report on ovarian mortality after long-term follow-up in UKCTOCS.MethodsIn this randomised controlled trial, postmenopausal aged 50–74 years were recruited from 13 centres National Health Service trusts England, Wales, and Northern Ireland....
The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic alone for women with high-risk endometrial cancer. We updated analysis to investigate patterns recurrence did a post-hoc survival analysis.In multicentre randomised phase 3 trial, cancer were eligible if they had International Federation Gynaecology Obstetrics (FIGO) 2009 stage I, endometrioid grade deep myometrial invasion or lymphovascular space invasion, both; II III disease; I-III...
Abstract Purpose: We investigated whether inhibition of interleukin 6 (IL-6) has therapeutic activity in ovarian cancer via abrogation a tumor-promoting cytokine network. Experimental Design: combined preclinical and silico experiments with phase 2 clinical trial the anti-IL-6 antibody siltuximab patients platinum-resistant cancer. Results: Automated immunohistochemistry on tissue microarrays from 221 cases showed that intensity IL-6 staining malignant cells significantly associated poor...
Lymph node metastases affect management and prognosis of patients with gynecologic malignancies. Preoperative nodal assessment computed tomography or magnetic resonance imaging (MRI) is inaccurate. A new lymph node-specific contrast agent, ferumoxtran-10, composed ultrasmall particles iron oxide (USPIO), may enhance the detection independent size. Our aim was to compare diagnostic performance MRI USPIO against standard size criteria.Forty-four endometrial (n = 15) cervical 29) cancer were...
Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns TILs by histotype and relation to other clinical factors.
Purpose To develop and validate a histopathologic scoring system for measuring response to neoadjuvant chemotherapy in interval debulking surgery specimens of stage IIIC IV tubo-ovarian high-grade serous carcinoma. Patients Methods A six-tier was proposed applied test cohort (TC) 62 patients treated with surgery. Adnexal omental sections were independently scored by three pathologists. On the basis TC results, three-tier score (CRS) developed an independent validation 71 patients. Results...
TP53 mutations are considered a surrogate biomarker of the serous-like 'copy number high' molecular subtype endometrial carcinoma (EC). In ovarian carcinoma, p53 immunohistochemistry (IHC) accurately reflects mutational status with almost 100% specificity but its performance in EC has not been established. This study tested whether IHC reliably predicts identified by next-generation sequencing (NGS) biopsy samples for all ECs and as part classification algorithm after exclusion cases...
There are no internationally agreed upon clinical guidelines as to which women with gynecological cancer would benefit from Lynch syndrome screening or how best manage the risk of in syndrome. The Manchester International Consensus Group was convened April 2017 address this unmet need. aim develop clear and comprehensive guidance regarding management sequelae based on existing evidence expert opinion medical professionals patients.
Purpose Cancer screening strategies have commonly adopted single-biomarker thresholds to identify abnormality. We investigated the impact of serial biomarker change interpreted through a risk algorithm on cancer detection rates. Patients and Methods In United Kingdom Collaborative Trial Ovarian Screening, 46,237 women, age 50 years or older underwent incidence by using multimodal strategy (MMS) in which annual serum antigen 125 (CA-125) was with ovarian (ROCA). Women were triaged ROCA:...
Purpose To establish the performance of screening with serum cancer antigen 125 (CA-125), interpreted using risk ovarian algorithm (ROCA), and transvaginal sonography (TVS) for women at high (OC) or fallopian tube (FTC). Patients Methods Women whose estimated lifetime OC/FTC was ≥ 10% were recruited 42 centers in United Kingdom underwent ROCA every 4 months. TVS occurred annually if results normal within 2 months an abnormal result. Risk-reducing salpingo-oophorectomy (RRSO) encouraged...
B-cells play a key role in cancer suppression, particularly when aggregated tertiary lymphoid structures (TLS). Here, we investigate the of and TLS endometrial (EC). Single cell RNA-sequencing shows presence naïve B-cells, cycling/germinal center antibody-secreting cells. Differential gene expression analysis association with L1CAM overexpression. Immunohistochemistry co-immunofluorescence show mature TLS, independent tumor. Using as marker, 378 411 molecularly classified ECs from PORTEC-3...
Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as subgroup with poorest prognosis most likely to benefit from adjuvant chemo(radio)therapy. P53abn are POLE wildtype, mismatch repair proficient show abnormal immunohistochemical (IHC) staining for p53. Correct interpretation routinely performed p53 IHC has therefore become paramount importance. We aimed comprehensively investigate patterns their relation...
The increase in the worldwide incidence of endometrial cancer relates to rising obesity, falling fertility, and ageing population. Transvaginal ultrasound (TVS) is a possible screening test, but there have been no large-scale studies. We report performance TVS large cohort.We did nested case-control study postmenopausal women who underwent United Kingdom Collaborative Trial Ovarian Cancer Screening (UKCTOCS) following recruitment between April 17, 2001, Sept 29, 2005. Endometrial thickness...
Although endometrial carcinoma (EC) is generally considered to have a good prognosis, over 20% of women with EC die their disease, projected increase in both incidence and mortality the next few decades. The aim accurate prognostication ensure that patients receive optimal treatment are neither overtreated nor undertreated, thereby improving patient outcomes overall. Patients can be categorized into prognostic risk groups based on clinicopathologic findings. Other than tumor type grade,...
To establish the performance characteristics of annual transvaginal ultrasound and serum CA125 screening for women at high risk ovarian/fallopian tube cancer (OC/FTC) to investigate impact delayed interval surgical intervention.Between May 6, 2002, January 5, 2008, 3,563 an estimated ≥ 10% lifetime OC/FTC were recruited screened by 37 centers in United Kingdom. Participants observed prospectively centers, questionnaire, national registries.Sensitivity detection incident 1 year after last...
The purpose of this study was to assess the effect neoadjuvant chemotherapy (NACT) on immune activation in stage IIIC/IV tubo-ovarian high-grade serous carcinoma (HGSC), and its relationship treatment response. We obtained pre- posttreatment omental biopsies blood samples from a total 54 patients undergoing platinum-based NACT 6 primary debulking surgery. measured T-cell density phenotype, activation, markers cancer-related inflammation using IHC, flow cytometry, electrochemiluminescence...